Trial Profile
A Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety of Pramlintide Treatment Employing Pramlintide Dose-Titration Followed by Insulin Dose Optimization in Subjects With Type 1 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Intensive Insulin Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pramlintide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Amylin Pharmaceuticals
- 18 Aug 2012 Status changed from not stated to completed as reported by ClinicalTrials.gov.
- 18 Aug 2012 New Source identified and integrated (NCT00042458: ClinicalTrials.gov: US National Institutes of Health).
- 05 Nov 2010 New trial record.